Maia Biotechnology (MAIA) said Tuesday that it has amended a 2021 clinical supply deal with Regeneron (REGN) to cover the expansion of a phase 2 clinical trial evaluating investigational drug THIO in non-small cell lung cancer.
According to the terms of the amended clinical supply agreement, Maia said Regeneron will provide its cancer drug Libtayo to treat all participants in the trial, including the additional patients in the expansion portion of the study.
The expansion part of the trial will further evaluate the efficacy of THIO sequenced with Libtayo in advanced non-small cell lung cancer patients receiving third-line therapy who were resistant to previous checkpoint inhibitor treatments and chemotherapy, Maia said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。